nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—restless legs syndrome—Pregabalin—epilepsy syndrome	0.126	0.267	CpDpCtD
L-DOPA—restless legs syndrome—Carbamazepine—epilepsy syndrome	0.112	0.238	CpDpCtD
L-DOPA—L-Phenylalanine—Felbamate—epilepsy syndrome	0.109	0.635	CrCrCtD
L-DOPA—restless legs syndrome—Clonazepam—epilepsy syndrome	0.0897	0.19	CpDpCtD
L-DOPA—CYP2D6—epilepsy syndrome	0.0837	1	CbGaD
L-DOPA—restless legs syndrome—Gabapentin—epilepsy syndrome	0.0723	0.153	CpDpCtD
L-DOPA—L-Phenylalanine—Lacosamide—epilepsy syndrome	0.0628	0.365	CrCrCtD
L-DOPA—Parkinson's disease—Clonazepam—epilepsy syndrome	0.0394	0.0835	CpDpCtD
L-DOPA—Parkinson's disease—Gabapentin—epilepsy syndrome	0.0317	0.0673	CpDpCtD
L-DOPA—DRD3—telencephalic ventricle—epilepsy syndrome	0.00245	0.0539	CbGeAlD
L-DOPA—DDC—telencephalic ventricle—epilepsy syndrome	0.00239	0.0526	CbGeAlD
L-DOPA—PSIP1—hindbrain—epilepsy syndrome	0.00198	0.0435	CbGeAlD
L-DOPA—DRD1—telencephalic ventricle—epilepsy syndrome	0.00175	0.0386	CbGeAlD
L-DOPA—SLC7A8—tongue—epilepsy syndrome	0.0017	0.0374	CbGeAlD
L-DOPA—DDC—ganglion—epilepsy syndrome	0.00149	0.0327	CbGeAlD
L-DOPA—DRD5—ganglion—epilepsy syndrome	0.00143	0.0315	CbGeAlD
L-DOPA—L-Tryptophan—WARS—epilepsy syndrome	0.0012	0.384	CrCbGaD
L-DOPA—PSIP1—brainstem—epilepsy syndrome	0.00113	0.0249	CbGeAlD
L-DOPA—DDC—hindbrain—epilepsy syndrome	0.00113	0.0248	CbGeAlD
L-DOPA—PSIP1—forebrain—epilepsy syndrome	0.00109	0.0241	CbGeAlD
L-DOPA—DRD1—ganglion—epilepsy syndrome	0.00109	0.024	CbGeAlD
L-DOPA—DRD2—telencephalic ventricle—epilepsy syndrome	0.00104	0.0228	CbGeAlD
L-DOPA—PSIP1—telencephalon—epilepsy syndrome	0.00101	0.0221	CbGeAlD
L-DOPA—PSIP1—medulla oblongata—epilepsy syndrome	0.00079	0.0174	CbGeAlD
L-DOPA—PSIP1—midbrain—epilepsy syndrome	0.000722	0.0159	CbGeAlD
L-DOPA—SLC7A8—forebrain—epilepsy syndrome	0.000721	0.0159	CbGeAlD
L-DOPA—PSIP1—spinal cord—epilepsy syndrome	0.000705	0.0155	CbGeAlD
L-DOPA—SLC7A8—telencephalon—epilepsy syndrome	0.000663	0.0146	CbGeAlD
L-DOPA—DDC—brainstem—epilepsy syndrome	0.000646	0.0142	CbGeAlD
L-DOPA—DRD2—ganglion—epilepsy syndrome	0.000645	0.0142	CbGeAlD
L-DOPA—PSIP1—head—epilepsy syndrome	0.000626	0.0138	CbGeAlD
L-DOPA—DDC—forebrain—epilepsy syndrome	0.000624	0.0137	CbGeAlD
L-DOPA—DRD5—forebrain—epilepsy syndrome	0.0006	0.0132	CbGeAlD
L-DOPA—PSIP1—nervous system—epilepsy syndrome	0.000594	0.0131	CbGeAlD
L-DOPA—Mimosine—CCL2—epilepsy syndrome	0.000591	0.189	CrCbGaD
L-DOPA—DDC—telencephalon—epilepsy syndrome	0.000573	0.0126	CbGeAlD
L-DOPA—PSIP1—central nervous system—epilepsy syndrome	0.000572	0.0126	CbGeAlD
L-DOPA—PSIP1—cerebellum—epilepsy syndrome	0.000559	0.0123	CbGeAlD
L-DOPA—DRD5—telencephalon—epilepsy syndrome	0.000551	0.0121	CbGeAlD
L-DOPA—SLC7A5—telencephalon—epilepsy syndrome	0.000514	0.0113	CbGeAlD
L-DOPA—DRD2—hindbrain—epilepsy syndrome	0.000489	0.0108	CbGeAlD
L-DOPA—DRD1—brainstem—epilepsy syndrome	0.000475	0.0105	CbGeAlD
L-DOPA—DRD1—forebrain—epilepsy syndrome	0.000458	0.0101	CbGeAlD
L-DOPA—PSIP1—brain—epilepsy syndrome	0.000454	0.00999	CbGeAlD
L-DOPA—DRD1—telencephalon—epilepsy syndrome	0.000421	0.00927	CbGeAlD
L-DOPA—SLC7A8—head—epilepsy syndrome	0.000413	0.00908	CbGeAlD
L-DOPA—DDC—midbrain—epilepsy syndrome	0.000412	0.00906	CbGeAlD
L-DOPA—SLC7A5—medulla oblongata—epilepsy syndrome	0.000404	0.00888	CbGeAlD
L-DOPA—SLC7A8—nervous system—epilepsy syndrome	0.000391	0.00861	CbGeAlD
L-DOPA—DRD4—brain—epilepsy syndrome	0.000378	0.00831	CbGeAlD
L-DOPA—SLC7A8—central nervous system—epilepsy syndrome	0.000377	0.00829	CbGeAlD
L-DOPA—SLC7A5—midbrain—epilepsy syndrome	0.000369	0.00812	CbGeAlD
L-DOPA—SLC7A8—cerebellum—epilepsy syndrome	0.000368	0.0081	CbGeAlD
L-DOPA—DRD3—head—epilepsy syndrome	0.000366	0.00807	CbGeAlD
L-DOPA—SLC7A5—spinal cord—epilepsy syndrome	0.00036	0.00792	CbGeAlD
L-DOPA—DDC—head—epilepsy syndrome	0.000357	0.00786	CbGeAlD
L-DOPA—DRD3—nervous system—epilepsy syndrome	0.000347	0.00765	CbGeAlD
L-DOPA—DRD5—head—epilepsy syndrome	0.000343	0.00756	CbGeAlD
L-DOPA—DDC—nervous system—epilepsy syndrome	0.000339	0.00745	CbGeAlD
L-DOPA—DRD3—central nervous system—epilepsy syndrome	0.000334	0.00736	CbGeAlD
L-DOPA—DDC—central nervous system—epilepsy syndrome	0.000326	0.00717	CbGeAlD
L-DOPA—DRD5—nervous system—epilepsy syndrome	0.000326	0.00717	CbGeAlD
L-DOPA—SLC7A5—head—epilepsy syndrome	0.00032	0.00704	CbGeAlD
L-DOPA—DRD5—central nervous system—epilepsy syndrome	0.000313	0.0069	CbGeAlD
L-DOPA—SLC7A5—nervous system—epilepsy syndrome	0.000303	0.00667	CbGeAlD
L-DOPA—DRD1—midbrain—epilepsy syndrome	0.000303	0.00666	CbGeAlD
L-DOPA—SLC7A8—brain—epilepsy syndrome	0.000299	0.00658	CbGeAlD
L-DOPA—CYP2D6—hindbrain—epilepsy syndrome	0.000294	0.00647	CbGeAlD
L-DOPA—SLC7A5—central nervous system—epilepsy syndrome	0.000292	0.00643	CbGeAlD
L-DOPA—SLC7A5—cerebellum—epilepsy syndrome	0.000285	0.00628	CbGeAlD
L-DOPA—DRD2—brainstem—epilepsy syndrome	0.000281	0.00617	CbGeAlD
L-DOPA—DRD2—forebrain—epilepsy syndrome	0.000271	0.00596	CbGeAlD
L-DOPA—DRD3—brain—epilepsy syndrome	0.000266	0.00584	CbGeAlD
L-DOPA—DRD1—head—epilepsy syndrome	0.000262	0.00578	CbGeAlD
L-DOPA—DDC—brain—epilepsy syndrome	0.000259	0.0057	CbGeAlD
L-DOPA—L-Tyrosine—TH—epilepsy syndrome	0.000254	0.0813	CrCbGaD
L-DOPA—DRD2—telencephalon—epilepsy syndrome	0.000249	0.00548	CbGeAlD
L-DOPA—DRD5—brain—epilepsy syndrome	0.000249	0.00548	CbGeAlD
L-DOPA—DRD1—nervous system—epilepsy syndrome	0.000249	0.00548	CbGeAlD
L-DOPA—DRD1—central nervous system—epilepsy syndrome	0.000239	0.00527	CbGeAlD
L-DOPA—SLC7A5—brain—epilepsy syndrome	0.000232	0.0051	CbGeAlD
L-DOPA—SLC16A10—cerebellum—epilepsy syndrome	0.000218	0.00481	CbGeAlD
L-DOPA—DRD1—brain—epilepsy syndrome	0.00019	0.00419	CbGeAlD
L-DOPA—DRD2—midbrain—epilepsy syndrome	0.000179	0.00394	CbGeAlD
L-DOPA—Liothyronine—SLCO1A2—epilepsy syndrome	0.00017	0.0545	CrCbGaD
L-DOPA—CYP2D6—brainstem—epilepsy syndrome	0.000169	0.00371	CbGeAlD
L-DOPA—CYP2D6—forebrain—epilepsy syndrome	0.000163	0.00358	CbGeAlD
L-DOPA—DRD2—head—epilepsy syndrome	0.000155	0.00341	CbGeAlD
L-DOPA—CYP2D6—telencephalon—epilepsy syndrome	0.00015	0.00329	CbGeAlD
L-DOPA—L-Phenylalanine—TH—epilepsy syndrome	0.000147	0.0472	CrCbGaD
L-DOPA—DRD2—nervous system—epilepsy syndrome	0.000147	0.00324	CbGeAlD
L-DOPA—DRD2—central nervous system—epilepsy syndrome	0.000141	0.00311	CbGeAlD
L-DOPA—DRD2—cerebellum—epilepsy syndrome	0.000138	0.00304	CbGeAlD
L-DOPA—DRD2—brain—epilepsy syndrome	0.000112	0.00247	CbGeAlD
L-DOPA—Methyldopa—ADRA2A—epilepsy syndrome	0.00011	0.0352	CrCbGaD
L-DOPA—Levonordefrin—ADRA2A—epilepsy syndrome	9.73e-05	0.0311	CrCbGaD
L-DOPA—CYP2D6—head—epilepsy syndrome	9.31e-05	0.00205	CbGeAlD
L-DOPA—CYP2D6—nervous system—epilepsy syndrome	8.83e-05	0.00194	CbGeAlD
L-DOPA—CYP2D6—central nervous system—epilepsy syndrome	8.5e-05	0.00187	CbGeAlD
L-DOPA—CYP2D6—cerebellum—epilepsy syndrome	8.31e-05	0.00183	CbGeAlD
L-DOPA—Droxidopa—ADRA2A—epilepsy syndrome	6.85e-05	0.0219	CrCbGaD
L-DOPA—CYP2D6—brain—epilepsy syndrome	6.75e-05	0.00149	CbGeAlD
L-DOPA—Dopamine—HTR7—epilepsy syndrome	6.25e-05	0.02	CrCbGaD
L-DOPA—Norepinephrine—ADRA2A—epilepsy syndrome	5.77e-05	0.0185	CrCbGaD
L-DOPA—Epinephrine—ADRA2A—epilepsy syndrome	5.24e-05	0.0168	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—epilepsy syndrome	5.22e-05	0.0167	CrCbGaD
L-DOPA—Epinephrine—TNF—epilepsy syndrome	4.96e-05	0.0159	CrCbGaD
L-DOPA—Mesalazine—PTGS2—epilepsy syndrome	4.09e-05	0.0131	CrCbGaD
L-DOPA—Dopamine—SLC6A4—epilepsy syndrome	4.09e-05	0.0131	CrCbGaD
L-DOPA—Dopamine—CYP2C19—epilepsy syndrome	3.88e-05	0.0124	CrCbGaD
L-DOPA—Thrombocytopenia—Valproic Acid—epilepsy syndrome	3.44e-05	0.000248	CcSEcCtD
L-DOPA—Palpitations—Pregabalin—epilepsy syndrome	3.43e-05	0.000247	CcSEcCtD
L-DOPA—Asthenia—Phenytoin—epilepsy syndrome	3.43e-05	0.000247	CcSEcCtD
L-DOPA—Nausea—Midazolam—epilepsy syndrome	3.43e-05	0.000247	CcSEcCtD
L-DOPA—Hallucination—Topiramate—epilepsy syndrome	3.43e-05	0.000247	CcSEcCtD
L-DOPA—Hypoaesthesia—Topiramate—epilepsy syndrome	3.43e-05	0.000247	CcSEcCtD
L-DOPA—Muscle spasms—Gabapentin—epilepsy syndrome	3.43e-05	0.000247	CcSEcCtD
L-DOPA—Diarrhoea—Zonisamide—epilepsy syndrome	3.42e-05	0.000246	CcSEcCtD
L-DOPA—Loss of consciousness—Pregabalin—epilepsy syndrome	3.42e-05	0.000246	CcSEcCtD
L-DOPA—Asthenia—Oxcarbazepine—epilepsy syndrome	3.42e-05	0.000246	CcSEcCtD
L-DOPA—Pruritus—Clonazepam—epilepsy syndrome	3.41e-05	0.000246	CcSEcCtD
L-DOPA—Vomiting—Vigabatrin—epilepsy syndrome	3.41e-05	0.000246	CcSEcCtD
L-DOPA—Urinary tract disorder—Topiramate—epilepsy syndrome	3.4e-05	0.000245	CcSEcCtD
L-DOPA—Hyperhidrosis—Valproic Acid—epilepsy syndrome	3.39e-05	0.000244	CcSEcCtD
L-DOPA—Cough—Pregabalin—epilepsy syndrome	3.39e-05	0.000244	CcSEcCtD
L-DOPA—Pruritus—Phenytoin—epilepsy syndrome	3.39e-05	0.000244	CcSEcCtD
L-DOPA—Nausea—Levetiracetam—epilepsy syndrome	3.38e-05	0.000244	CcSEcCtD
L-DOPA—Rash—Vigabatrin—epilepsy syndrome	3.38e-05	0.000244	CcSEcCtD
L-DOPA—Dizziness—Felbamate—epilepsy syndrome	3.38e-05	0.000243	CcSEcCtD
L-DOPA—Dermatitis—Vigabatrin—epilepsy syndrome	3.38e-05	0.000243	CcSEcCtD
L-DOPA—Urethral disorder—Topiramate—epilepsy syndrome	3.38e-05	0.000243	CcSEcCtD
L-DOPA—Pruritus—Oxcarbazepine—epilepsy syndrome	3.37e-05	0.000243	CcSEcCtD
L-DOPA—Convulsion—Pregabalin—epilepsy syndrome	3.37e-05	0.000243	CcSEcCtD
L-DOPA—Hypersensitivity—Carbamazepine—epilepsy syndrome	3.37e-05	0.000243	CcSEcCtD
L-DOPA—Vision blurred—Gabapentin—epilepsy syndrome	3.36e-05	0.000242	CcSEcCtD
L-DOPA—Headache—Vigabatrin—epilepsy syndrome	3.36e-05	0.000242	CcSEcCtD
L-DOPA—Hypertension—Pregabalin—epilepsy syndrome	3.36e-05	0.000242	CcSEcCtD
L-DOPA—Vomiting—Diazepam—epilepsy syndrome	3.36e-05	0.000242	CcSEcCtD
L-DOPA—Anorexia—Valproic Acid—epilepsy syndrome	3.34e-05	0.000241	CcSEcCtD
L-DOPA—Tremor—Gabapentin—epilepsy syndrome	3.34e-05	0.000241	CcSEcCtD
L-DOPA—Rash—Diazepam—epilepsy syndrome	3.33e-05	0.00024	CcSEcCtD
L-DOPA—Dermatitis—Diazepam—epilepsy syndrome	3.32e-05	0.00024	CcSEcCtD
L-DOPA—Chest pain—Pregabalin—epilepsy syndrome	3.31e-05	0.000238	CcSEcCtD
L-DOPA—Ill-defined disorder—Gabapentin—epilepsy syndrome	3.31e-05	0.000238	CcSEcCtD
L-DOPA—Dizziness—Zonisamide—epilepsy syndrome	3.31e-05	0.000238	CcSEcCtD
L-DOPA—Headache—Diazepam—epilepsy syndrome	3.31e-05	0.000238	CcSEcCtD
L-DOPA—Anxiety—Pregabalin—epilepsy syndrome	3.3e-05	0.000238	CcSEcCtD
L-DOPA—Diarrhoea—Clonazepam—epilepsy syndrome	3.3e-05	0.000238	CcSEcCtD
L-DOPA—Anaemia—Gabapentin—epilepsy syndrome	3.29e-05	0.000237	CcSEcCtD
L-DOPA—Hypotension—Valproic Acid—epilepsy syndrome	3.28e-05	0.000236	CcSEcCtD
L-DOPA—Asthenia—Carbamazepine—epilepsy syndrome	3.28e-05	0.000236	CcSEcCtD
L-DOPA—Agitation—Gabapentin—epilepsy syndrome	3.28e-05	0.000236	CcSEcCtD
L-DOPA—Diarrhoea—Phenytoin—epilepsy syndrome	3.27e-05	0.000236	CcSEcCtD
L-DOPA—Discomfort—Pregabalin—epilepsy syndrome	3.27e-05	0.000236	CcSEcCtD
L-DOPA—Nausea—Fosphenytoin—epilepsy syndrome	3.27e-05	0.000235	CcSEcCtD
L-DOPA—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.26e-05	0.000235	CcSEcCtD
L-DOPA—Angioedema—Gabapentin—epilepsy syndrome	3.26e-05	0.000235	CcSEcCtD
L-DOPA—Hypersensitivity—Lamotrigine—epilepsy syndrome	3.25e-05	0.000234	CcSEcCtD
L-DOPA—Vomiting—Felbamate—epilepsy syndrome	3.25e-05	0.000234	CcSEcCtD
L-DOPA—Dry mouth—Pregabalin—epilepsy syndrome	3.24e-05	0.000233	CcSEcCtD
L-DOPA—Pruritus—Carbamazepine—epilepsy syndrome	3.23e-05	0.000233	CcSEcCtD
L-DOPA—Rash—Felbamate—epilepsy syndrome	3.22e-05	0.000232	CcSEcCtD
L-DOPA—Dermatitis—Felbamate—epilepsy syndrome	3.22e-05	0.000232	CcSEcCtD
L-DOPA—Malaise—Gabapentin—epilepsy syndrome	3.21e-05	0.000232	CcSEcCtD
L-DOPA—Headache—Felbamate—epilepsy syndrome	3.2e-05	0.000231	CcSEcCtD
L-DOPA—Confusional state—Pregabalin—epilepsy syndrome	3.2e-05	0.00023	CcSEcCtD
L-DOPA—Flushing—Topiramate—epilepsy syndrome	3.2e-05	0.00023	CcSEcCtD
L-DOPA—Syncope—Gabapentin—epilepsy syndrome	3.2e-05	0.00023	CcSEcCtD
L-DOPA—Leukopenia—Gabapentin—epilepsy syndrome	3.19e-05	0.00023	CcSEcCtD
L-DOPA—Dizziness—Clonazepam—epilepsy syndrome	3.19e-05	0.00023	CcSEcCtD
L-DOPA—Nausea—Vigabatrin—epilepsy syndrome	3.18e-05	0.000229	CcSEcCtD
L-DOPA—Vomiting—Zonisamide—epilepsy syndrome	3.18e-05	0.000229	CcSEcCtD
L-DOPA—Insomnia—Valproic Acid—epilepsy syndrome	3.17e-05	0.000229	CcSEcCtD
L-DOPA—Oedema—Pregabalin—epilepsy syndrome	3.17e-05	0.000229	CcSEcCtD
L-DOPA—Asthenia—Lamotrigine—epilepsy syndrome	3.17e-05	0.000228	CcSEcCtD
L-DOPA—Dizziness—Phenytoin—epilepsy syndrome	3.16e-05	0.000228	CcSEcCtD
L-DOPA—Rash—Zonisamide—epilepsy syndrome	3.15e-05	0.000227	CcSEcCtD
L-DOPA—Paraesthesia—Valproic Acid—epilepsy syndrome	3.15e-05	0.000227	CcSEcCtD
L-DOPA—Palpitations—Gabapentin—epilepsy syndrome	3.15e-05	0.000227	CcSEcCtD
L-DOPA—Dermatitis—Zonisamide—epilepsy syndrome	3.15e-05	0.000227	CcSEcCtD
L-DOPA—Dizziness—Oxcarbazepine—epilepsy syndrome	3.15e-05	0.000227	CcSEcCtD
L-DOPA—Liothyronine—ALB—epilepsy syndrome	3.14e-05	0.01	CrCbGaD
L-DOPA—Nausea—Diazepam—epilepsy syndrome	3.13e-05	0.000226	CcSEcCtD
L-DOPA—Loss of consciousness—Gabapentin—epilepsy syndrome	3.13e-05	0.000226	CcSEcCtD
L-DOPA—Headache—Zonisamide—epilepsy syndrome	3.13e-05	0.000226	CcSEcCtD
L-DOPA—Dyspnoea—Valproic Acid—epilepsy syndrome	3.13e-05	0.000225	CcSEcCtD
L-DOPA—Diarrhoea—Carbamazepine—epilepsy syndrome	3.13e-05	0.000225	CcSEcCtD
L-DOPA—Pruritus—Lamotrigine—epilepsy syndrome	3.12e-05	0.000225	CcSEcCtD
L-DOPA—Shock—Pregabalin—epilepsy syndrome	3.12e-05	0.000225	CcSEcCtD
L-DOPA—Somnolence—Valproic Acid—epilepsy syndrome	3.12e-05	0.000225	CcSEcCtD
L-DOPA—Cough—Gabapentin—epilepsy syndrome	3.11e-05	0.000224	CcSEcCtD
L-DOPA—Thrombocytopenia—Pregabalin—epilepsy syndrome	3.11e-05	0.000224	CcSEcCtD
L-DOPA—Dyspepsia—Valproic Acid—epilepsy syndrome	3.09e-05	0.000223	CcSEcCtD
L-DOPA—Convulsion—Gabapentin—epilepsy syndrome	3.09e-05	0.000223	CcSEcCtD
L-DOPA—Hypertension—Gabapentin—epilepsy syndrome	3.08e-05	0.000222	CcSEcCtD
L-DOPA—Hyperhidrosis—Pregabalin—epilepsy syndrome	3.07e-05	0.000221	CcSEcCtD
L-DOPA—Vomiting—Clonazepam—epilepsy syndrome	3.06e-05	0.000221	CcSEcCtD
L-DOPA—Decreased appetite—Valproic Acid—epilepsy syndrome	3.05e-05	0.00022	CcSEcCtD
L-DOPA—Alopecia—Topiramate—epilepsy syndrome	3.04e-05	0.000219	CcSEcCtD
L-DOPA—Vomiting—Phenytoin—epilepsy syndrome	3.04e-05	0.000219	CcSEcCtD
L-DOPA—Rash—Clonazepam—epilepsy syndrome	3.04e-05	0.000219	CcSEcCtD
L-DOPA—Dermatitis—Clonazepam—epilepsy syndrome	3.04e-05	0.000219	CcSEcCtD
L-DOPA—Chest pain—Gabapentin—epilepsy syndrome	3.03e-05	0.000219	CcSEcCtD
L-DOPA—Nausea—Felbamate—epilepsy syndrome	3.03e-05	0.000219	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.03e-05	0.000218	CcSEcCtD
L-DOPA—Vomiting—Oxcarbazepine—epilepsy syndrome	3.03e-05	0.000218	CcSEcCtD
L-DOPA—Fatigue—Valproic Acid—epilepsy syndrome	3.02e-05	0.000218	CcSEcCtD
L-DOPA—Anxiety—Gabapentin—epilepsy syndrome	3.02e-05	0.000218	CcSEcCtD
L-DOPA—Anorexia—Pregabalin—epilepsy syndrome	3.02e-05	0.000218	CcSEcCtD
L-DOPA—Dizziness—Carbamazepine—epilepsy syndrome	3.02e-05	0.000218	CcSEcCtD
L-DOPA—Diarrhoea—Lamotrigine—epilepsy syndrome	3.02e-05	0.000218	CcSEcCtD
L-DOPA—Headache—Clonazepam—epilepsy syndrome	3.02e-05	0.000218	CcSEcCtD
L-DOPA—Rash—Phenytoin—epilepsy syndrome	3.02e-05	0.000217	CcSEcCtD
L-DOPA—Mental disorder—Topiramate—epilepsy syndrome	3.02e-05	0.000217	CcSEcCtD
L-DOPA—Dermatitis—Phenytoin—epilepsy syndrome	3.01e-05	0.000217	CcSEcCtD
L-DOPA—Rash—Oxcarbazepine—epilepsy syndrome	3e-05	0.000216	CcSEcCtD
L-DOPA—Pain—Valproic Acid—epilepsy syndrome	3e-05	0.000216	CcSEcCtD
L-DOPA—Constipation—Valproic Acid—epilepsy syndrome	3e-05	0.000216	CcSEcCtD
L-DOPA—Dermatitis—Oxcarbazepine—epilepsy syndrome	3e-05	0.000216	CcSEcCtD
L-DOPA—Headache—Phenytoin—epilepsy syndrome	3e-05	0.000216	CcSEcCtD
L-DOPA—Discomfort—Gabapentin—epilepsy syndrome	3e-05	0.000216	CcSEcCtD
L-DOPA—Liothyronine—ABCB1—epilepsy syndrome	3e-05	0.00959	CrCbGaD
L-DOPA—Headache—Oxcarbazepine—epilepsy syndrome	2.98e-05	0.000215	CcSEcCtD
L-DOPA—Nausea—Zonisamide—epilepsy syndrome	2.97e-05	0.000214	CcSEcCtD
L-DOPA—Dry mouth—Gabapentin—epilepsy syndrome	2.97e-05	0.000214	CcSEcCtD
L-DOPA—Hypotension—Pregabalin—epilepsy syndrome	2.96e-05	0.000214	CcSEcCtD
L-DOPA—Flatulence—Topiramate—epilepsy syndrome	2.95e-05	0.000213	CcSEcCtD
L-DOPA—Tension—Topiramate—epilepsy syndrome	2.94e-05	0.000212	CcSEcCtD
L-DOPA—Dysgeusia—Topiramate—epilepsy syndrome	2.94e-05	0.000212	CcSEcCtD
L-DOPA—Confusional state—Gabapentin—epilepsy syndrome	2.93e-05	0.000211	CcSEcCtD
L-DOPA—Dizziness—Lamotrigine—epilepsy syndrome	2.92e-05	0.00021	CcSEcCtD
L-DOPA—Nervousness—Topiramate—epilepsy syndrome	2.91e-05	0.00021	CcSEcCtD
L-DOPA—Oedema—Gabapentin—epilepsy syndrome	2.91e-05	0.00021	CcSEcCtD
L-DOPA—Vomiting—Carbamazepine—epilepsy syndrome	2.9e-05	0.000209	CcSEcCtD
L-DOPA—Back pain—Topiramate—epilepsy syndrome	2.9e-05	0.000209	CcSEcCtD
L-DOPA—Feeling abnormal—Valproic Acid—epilepsy syndrome	2.89e-05	0.000208	CcSEcCtD
L-DOPA—Muscle spasms—Topiramate—epilepsy syndrome	2.88e-05	0.000208	CcSEcCtD
L-DOPA—Rash—Carbamazepine—epilepsy syndrome	2.88e-05	0.000208	CcSEcCtD
L-DOPA—Dermatitis—Carbamazepine—epilepsy syndrome	2.88e-05	0.000207	CcSEcCtD
L-DOPA—Dopamine—CYP2D6—epilepsy syndrome	2.88e-05	0.00921	CrCbGaD
L-DOPA—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	2.87e-05	0.000207	CcSEcCtD
L-DOPA—Insomnia—Pregabalin—epilepsy syndrome	2.87e-05	0.000207	CcSEcCtD
L-DOPA—Nausea—Clonazepam—epilepsy syndrome	2.86e-05	0.000206	CcSEcCtD
L-DOPA—Headache—Carbamazepine—epilepsy syndrome	2.86e-05	0.000206	CcSEcCtD
L-DOPA—Shock—Gabapentin—epilepsy syndrome	2.86e-05	0.000206	CcSEcCtD
L-DOPA—Paraesthesia—Pregabalin—epilepsy syndrome	2.85e-05	0.000205	CcSEcCtD
L-DOPA—Thrombocytopenia—Gabapentin—epilepsy syndrome	2.85e-05	0.000205	CcSEcCtD
L-DOPA—Nausea—Phenytoin—epilepsy syndrome	2.84e-05	0.000205	CcSEcCtD
L-DOPA—Dyspnoea—Pregabalin—epilepsy syndrome	2.83e-05	0.000204	CcSEcCtD
L-DOPA—Nausea—Oxcarbazepine—epilepsy syndrome	2.83e-05	0.000204	CcSEcCtD
L-DOPA—Vision blurred—Topiramate—epilepsy syndrome	2.83e-05	0.000204	CcSEcCtD
L-DOPA—Somnolence—Pregabalin—epilepsy syndrome	2.82e-05	0.000203	CcSEcCtD
L-DOPA—Hyperhidrosis—Gabapentin—epilepsy syndrome	2.81e-05	0.000203	CcSEcCtD
L-DOPA—Tremor—Topiramate—epilepsy syndrome	2.81e-05	0.000202	CcSEcCtD
L-DOPA—Vomiting—Lamotrigine—epilepsy syndrome	2.81e-05	0.000202	CcSEcCtD
L-DOPA—Urticaria—Valproic Acid—epilepsy syndrome	2.79e-05	0.000201	CcSEcCtD
L-DOPA—Rash—Lamotrigine—epilepsy syndrome	2.78e-05	0.000201	CcSEcCtD
L-DOPA—Ill-defined disorder—Topiramate—epilepsy syndrome	2.78e-05	0.0002	CcSEcCtD
L-DOPA—Dermatitis—Lamotrigine—epilepsy syndrome	2.78e-05	0.0002	CcSEcCtD
L-DOPA—Abdominal pain—Valproic Acid—epilepsy syndrome	2.77e-05	0.0002	CcSEcCtD
L-DOPA—Anorexia—Gabapentin—epilepsy syndrome	2.77e-05	0.0002	CcSEcCtD
L-DOPA—Anaemia—Topiramate—epilepsy syndrome	2.77e-05	0.0002	CcSEcCtD
L-DOPA—Headache—Lamotrigine—epilepsy syndrome	2.77e-05	0.000199	CcSEcCtD
L-DOPA—Decreased appetite—Pregabalin—epilepsy syndrome	2.76e-05	0.000199	CcSEcCtD
L-DOPA—Agitation—Topiramate—epilepsy syndrome	2.76e-05	0.000199	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	2.74e-05	0.000197	CcSEcCtD
L-DOPA—Fatigue—Pregabalin—epilepsy syndrome	2.73e-05	0.000197	CcSEcCtD
L-DOPA—Hypotension—Gabapentin—epilepsy syndrome	2.72e-05	0.000196	CcSEcCtD
L-DOPA—Nausea—Carbamazepine—epilepsy syndrome	2.71e-05	0.000196	CcSEcCtD
L-DOPA—Pain—Pregabalin—epilepsy syndrome	2.71e-05	0.000195	CcSEcCtD
L-DOPA—Constipation—Pregabalin—epilepsy syndrome	2.71e-05	0.000195	CcSEcCtD
L-DOPA—Malaise—Topiramate—epilepsy syndrome	2.7e-05	0.000195	CcSEcCtD
L-DOPA—Syncope—Topiramate—epilepsy syndrome	2.69e-05	0.000194	CcSEcCtD
L-DOPA—Leukopenia—Topiramate—epilepsy syndrome	2.68e-05	0.000193	CcSEcCtD
L-DOPA—Palpitations—Topiramate—epilepsy syndrome	2.65e-05	0.000191	CcSEcCtD
L-DOPA—Loss of consciousness—Topiramate—epilepsy syndrome	2.64e-05	0.00019	CcSEcCtD
L-DOPA—Insomnia—Gabapentin—epilepsy syndrome	2.63e-05	0.00019	CcSEcCtD
L-DOPA—Nausea—Lamotrigine—epilepsy syndrome	2.62e-05	0.000189	CcSEcCtD
L-DOPA—Cough—Topiramate—epilepsy syndrome	2.62e-05	0.000189	CcSEcCtD
L-DOPA—Feeling abnormal—Pregabalin—epilepsy syndrome	2.61e-05	0.000188	CcSEcCtD
L-DOPA—Paraesthesia—Gabapentin—epilepsy syndrome	2.61e-05	0.000188	CcSEcCtD
L-DOPA—Convulsion—Topiramate—epilepsy syndrome	2.6e-05	0.000187	CcSEcCtD
L-DOPA—Gastrointestinal pain—Pregabalin—epilepsy syndrome	2.59e-05	0.000187	CcSEcCtD
L-DOPA—Dyspnoea—Gabapentin—epilepsy syndrome	2.59e-05	0.000187	CcSEcCtD
L-DOPA—Hypertension—Topiramate—epilepsy syndrome	2.59e-05	0.000187	CcSEcCtD
L-DOPA—Somnolence—Gabapentin—epilepsy syndrome	2.59e-05	0.000186	CcSEcCtD
L-DOPA—Hypersensitivity—Valproic Acid—epilepsy syndrome	2.58e-05	0.000186	CcSEcCtD
L-DOPA—Dyspepsia—Gabapentin—epilepsy syndrome	2.56e-05	0.000184	CcSEcCtD
L-DOPA—Chest pain—Topiramate—epilepsy syndrome	2.55e-05	0.000184	CcSEcCtD
L-DOPA—Anxiety—Topiramate—epilepsy syndrome	2.54e-05	0.000183	CcSEcCtD
L-DOPA—Decreased appetite—Gabapentin—epilepsy syndrome	2.53e-05	0.000182	CcSEcCtD
L-DOPA—Discomfort—Topiramate—epilepsy syndrome	2.52e-05	0.000182	CcSEcCtD
L-DOPA—Urticaria—Pregabalin—epilepsy syndrome	2.52e-05	0.000182	CcSEcCtD
L-DOPA—Asthenia—Valproic Acid—epilepsy syndrome	2.52e-05	0.000181	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.51e-05	0.000181	CcSEcCtD
L-DOPA—Fatigue—Gabapentin—epilepsy syndrome	2.51e-05	0.000181	CcSEcCtD
L-DOPA—Abdominal pain—Pregabalin—epilepsy syndrome	2.51e-05	0.000181	CcSEcCtD
L-DOPA—Dry mouth—Topiramate—epilepsy syndrome	2.5e-05	0.00018	CcSEcCtD
L-DOPA—Constipation—Gabapentin—epilepsy syndrome	2.49e-05	0.000179	CcSEcCtD
L-DOPA—Pain—Gabapentin—epilepsy syndrome	2.49e-05	0.000179	CcSEcCtD
L-DOPA—Pruritus—Valproic Acid—epilepsy syndrome	2.48e-05	0.000179	CcSEcCtD
L-DOPA—Confusional state—Topiramate—epilepsy syndrome	2.47e-05	0.000178	CcSEcCtD
L-DOPA—Oedema—Topiramate—epilepsy syndrome	2.45e-05	0.000176	CcSEcCtD
L-DOPA—Shock—Topiramate—epilepsy syndrome	2.41e-05	0.000173	CcSEcCtD
L-DOPA—Diarrhoea—Valproic Acid—epilepsy syndrome	2.4e-05	0.000173	CcSEcCtD
L-DOPA—Feeling abnormal—Gabapentin—epilepsy syndrome	2.4e-05	0.000173	CcSEcCtD
L-DOPA—Thrombocytopenia—Topiramate—epilepsy syndrome	2.4e-05	0.000173	CcSEcCtD
L-DOPA—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.38e-05	0.000171	CcSEcCtD
L-DOPA—Hyperhidrosis—Topiramate—epilepsy syndrome	2.37e-05	0.00017	CcSEcCtD
L-DOPA—Hypersensitivity—Pregabalin—epilepsy syndrome	2.34e-05	0.000168	CcSEcCtD
L-DOPA—Anorexia—Topiramate—epilepsy syndrome	2.33e-05	0.000168	CcSEcCtD
L-DOPA—Dizziness—Valproic Acid—epilepsy syndrome	2.32e-05	0.000167	CcSEcCtD
L-DOPA—Urticaria—Gabapentin—epilepsy syndrome	2.31e-05	0.000167	CcSEcCtD
L-DOPA—Abdominal pain—Gabapentin—epilepsy syndrome	2.3e-05	0.000166	CcSEcCtD
L-DOPA—Hypotension—Topiramate—epilepsy syndrome	2.29e-05	0.000165	CcSEcCtD
L-DOPA—Asthenia—Pregabalin—epilepsy syndrome	2.28e-05	0.000164	CcSEcCtD
L-DOPA—Pruritus—Pregabalin—epilepsy syndrome	2.24e-05	0.000162	CcSEcCtD
L-DOPA—Vomiting—Valproic Acid—epilepsy syndrome	2.23e-05	0.000161	CcSEcCtD
L-DOPA—Insomnia—Topiramate—epilepsy syndrome	2.21e-05	0.000159	CcSEcCtD
L-DOPA—Rash—Valproic Acid—epilepsy syndrome	2.21e-05	0.000159	CcSEcCtD
L-DOPA—Dermatitis—Valproic Acid—epilepsy syndrome	2.21e-05	0.000159	CcSEcCtD
L-DOPA—Headache—Valproic Acid—epilepsy syndrome	2.2e-05	0.000158	CcSEcCtD
L-DOPA—Paraesthesia—Topiramate—epilepsy syndrome	2.2e-05	0.000158	CcSEcCtD
L-DOPA—Dyspnoea—Topiramate—epilepsy syndrome	2.18e-05	0.000157	CcSEcCtD
L-DOPA—Somnolence—Topiramate—epilepsy syndrome	2.18e-05	0.000157	CcSEcCtD
L-DOPA—Diarrhoea—Pregabalin—epilepsy syndrome	2.17e-05	0.000156	CcSEcCtD
L-DOPA—Dyspepsia—Topiramate—epilepsy syndrome	2.15e-05	0.000155	CcSEcCtD
L-DOPA—Hypersensitivity—Gabapentin—epilepsy syndrome	2.14e-05	0.000154	CcSEcCtD
L-DOPA—Decreased appetite—Topiramate—epilepsy syndrome	2.13e-05	0.000153	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.11e-05	0.000152	CcSEcCtD
L-DOPA—Fatigue—Topiramate—epilepsy syndrome	2.11e-05	0.000152	CcSEcCtD
L-DOPA—Dizziness—Pregabalin—epilepsy syndrome	2.1e-05	0.000151	CcSEcCtD
L-DOPA—Pain—Topiramate—epilepsy syndrome	2.09e-05	0.000151	CcSEcCtD
L-DOPA—Constipation—Topiramate—epilepsy syndrome	2.09e-05	0.000151	CcSEcCtD
L-DOPA—Asthenia—Gabapentin—epilepsy syndrome	2.09e-05	0.00015	CcSEcCtD
L-DOPA—Nausea—Valproic Acid—epilepsy syndrome	2.08e-05	0.00015	CcSEcCtD
L-DOPA—Pruritus—Gabapentin—epilepsy syndrome	2.06e-05	0.000148	CcSEcCtD
L-DOPA—Vomiting—Pregabalin—epilepsy syndrome	2.02e-05	0.000145	CcSEcCtD
L-DOPA—Feeling abnormal—Topiramate—epilepsy syndrome	2.02e-05	0.000145	CcSEcCtD
L-DOPA—Gastrointestinal pain—Topiramate—epilepsy syndrome	2e-05	0.000144	CcSEcCtD
L-DOPA—Rash—Pregabalin—epilepsy syndrome	2e-05	0.000144	CcSEcCtD
L-DOPA—Dermatitis—Pregabalin—epilepsy syndrome	2e-05	0.000144	CcSEcCtD
L-DOPA—Diarrhoea—Gabapentin—epilepsy syndrome	1.99e-05	0.000143	CcSEcCtD
L-DOPA—Headache—Pregabalin—epilepsy syndrome	1.99e-05	0.000143	CcSEcCtD
L-DOPA—Urticaria—Topiramate—epilepsy syndrome	1.94e-05	0.00014	CcSEcCtD
L-DOPA—Abdominal pain—Topiramate—epilepsy syndrome	1.93e-05	0.000139	CcSEcCtD
L-DOPA—Dizziness—Gabapentin—epilepsy syndrome	1.92e-05	0.000139	CcSEcCtD
L-DOPA—Nausea—Pregabalin—epilepsy syndrome	1.88e-05	0.000136	CcSEcCtD
L-DOPA—Vomiting—Gabapentin—epilepsy syndrome	1.85e-05	0.000133	CcSEcCtD
L-DOPA—Rash—Gabapentin—epilepsy syndrome	1.83e-05	0.000132	CcSEcCtD
L-DOPA—Dermatitis—Gabapentin—epilepsy syndrome	1.83e-05	0.000132	CcSEcCtD
L-DOPA—Headache—Gabapentin—epilepsy syndrome	1.82e-05	0.000131	CcSEcCtD
L-DOPA—Hypersensitivity—Topiramate—epilepsy syndrome	1.8e-05	0.00013	CcSEcCtD
L-DOPA—Asthenia—Topiramate—epilepsy syndrome	1.76e-05	0.000127	CcSEcCtD
L-DOPA—Pruritus—Topiramate—epilepsy syndrome	1.73e-05	0.000125	CcSEcCtD
L-DOPA—Nausea—Gabapentin—epilepsy syndrome	1.73e-05	0.000124	CcSEcCtD
L-DOPA—Diarrhoea—Topiramate—epilepsy syndrome	1.67e-05	0.000121	CcSEcCtD
L-DOPA—Dizziness—Topiramate—epilepsy syndrome	1.62e-05	0.000117	CcSEcCtD
L-DOPA—Vomiting—Topiramate—epilepsy syndrome	1.56e-05	0.000112	CcSEcCtD
L-DOPA—Rash—Topiramate—epilepsy syndrome	1.54e-05	0.000111	CcSEcCtD
L-DOPA—Dermatitis—Topiramate—epilepsy syndrome	1.54e-05	0.000111	CcSEcCtD
L-DOPA—Headache—Topiramate—epilepsy syndrome	1.53e-05	0.00011	CcSEcCtD
L-DOPA—Nausea—Topiramate—epilepsy syndrome	1.45e-05	0.000105	CcSEcCtD
L-DOPA—DRD1—Signaling Pathways—ADRA2A—epilepsy syndrome	3.26e-06	3.81e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DUSP6—epilepsy syndrome	3.26e-06	3.81e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PLAT—epilepsy syndrome	3.25e-06	3.8e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HBEGF—epilepsy syndrome	3.23e-06	3.78e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR5—epilepsy syndrome	3.23e-06	3.78e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AVP—epilepsy syndrome	3.23e-06	3.77e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADRA2A—epilepsy syndrome	3.22e-06	3.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PLAT—epilepsy syndrome	3.2e-06	3.74e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADSL—epilepsy syndrome	3.2e-06	3.74e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRH3—epilepsy syndrome	3.18e-06	3.72e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT3—epilepsy syndrome	3.17e-06	3.71e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HTR2A—epilepsy syndrome	3.16e-06	3.7e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—POMC—epilepsy syndrome	3.15e-06	3.69e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GLUL—epilepsy syndrome	3.14e-06	3.67e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—OPRM1—epilepsy syndrome	3.13e-06	3.66e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL12—epilepsy syndrome	3.13e-06	3.66e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BDKRB2—epilepsy syndrome	3.13e-06	3.66e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—POMC—epilepsy syndrome	3.13e-06	3.66e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PRKCB—epilepsy syndrome	3.12e-06	3.65e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6ST—epilepsy syndrome	3.1e-06	3.63e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADAM10—epilepsy syndrome	3.1e-06	3.63e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL12—epilepsy syndrome	3.09e-06	3.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BDKRB2—epilepsy syndrome	3.09e-06	3.61e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL2—epilepsy syndrome	3.09e-06	3.61e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—POMC—epilepsy syndrome	3.09e-06	3.61e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CACNA1D—epilepsy syndrome	3.08e-06	3.6e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PRKCB—epilepsy syndrome	3.08e-06	3.6e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUNB—epilepsy syndrome	3.07e-06	3.59e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CNR1—epilepsy syndrome	3.07e-06	3.59e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—epilepsy syndrome	3.06e-06	3.58e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6ST—epilepsy syndrome	3.06e-06	3.58e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PLCB1—epilepsy syndrome	3.06e-06	3.58e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUNB—epilepsy syndrome	3.03e-06	3.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CNR1—epilepsy syndrome	3.03e-06	3.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PLCB1—epilepsy syndrome	3.02e-06	3.53e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR5—epilepsy syndrome	3.02e-06	3.53e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TSC2—epilepsy syndrome	3e-06	3.51e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AGT—epilepsy syndrome	3e-06	3.51e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR7—epilepsy syndrome	3e-06	3.51e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR7—epilepsy syndrome	2.96e-06	3.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR3—epilepsy syndrome	2.96e-06	3.46e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HTR2A—epilepsy syndrome	2.96e-06	3.46e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APOE—epilepsy syndrome	2.94e-06	3.44e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—S100B—epilepsy syndrome	2.93e-06	3.43e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HBEGF—epilepsy syndrome	2.91e-06	3.4e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SOCS3—epilepsy syndrome	2.9e-06	3.39e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDC42—epilepsy syndrome	2.9e-06	3.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	2.88e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NPY—epilepsy syndrome	2.88e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ATP2A2—epilepsy syndrome	2.88e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KDR—epilepsy syndrome	2.88e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HBEGF—epilepsy syndrome	2.87e-06	3.36e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT3—epilepsy syndrome	2.86e-06	3.34e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—POMC—epilepsy syndrome	2.84e-06	3.32e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT3—epilepsy syndrome	2.82e-06	3.3e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AGT—epilepsy syndrome	2.8e-06	3.28e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AVP—epilepsy syndrome	2.8e-06	3.28e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—POMC—epilepsy syndrome	2.8e-06	3.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AQP1—epilepsy syndrome	2.8e-06	3.27e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADAM10—epilepsy syndrome	2.79e-06	3.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—OXT—epilepsy syndrome	2.78e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CRH—epilepsy syndrome	2.78e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HSPB1—epilepsy syndrome	2.78e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL2—epilepsy syndrome	2.78e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL3—epilepsy syndrome	2.78e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL2—epilepsy syndrome	2.78e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PRKCB—epilepsy syndrome	2.77e-06	3.24e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6ST—epilepsy syndrome	2.76e-06	3.23e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADAM10—epilepsy syndrome	2.75e-06	3.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR5—epilepsy syndrome	2.74e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL2—epilepsy syndrome	2.74e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HTR2A—epilepsy syndrome	2.68e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HES1—epilepsy syndrome	2.65e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—S100B—epilepsy syndrome	2.64e-06	3.09e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SOCS3—epilepsy syndrome	2.61e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDC42—epilepsy syndrome	2.61e-06	3.05e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—S100B—epilepsy syndrome	2.6e-06	3.05e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PRKCB—epilepsy syndrome	2.59e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTK2B—epilepsy syndrome	2.59e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSC1—epilepsy syndrome	2.59e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SOCS3—epilepsy syndrome	2.58e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FYN—epilepsy syndrome	2.58e-06	3.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDC42—epilepsy syndrome	2.57e-06	3.01e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—H2AFX—epilepsy syndrome	2.57e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MEF2C—epilepsy syndrome	2.56e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AGT—epilepsy syndrome	2.55e-06	2.98e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	2.53e-06	2.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	2.53e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—POMC—epilepsy syndrome	2.52e-06	2.95e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AVP—epilepsy syndrome	2.52e-06	2.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SST—epilepsy syndrome	2.51e-06	2.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR2—epilepsy syndrome	2.51e-06	2.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NTRK2—epilepsy syndrome	2.51e-06	2.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DUSP6—epilepsy syndrome	2.49e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AVP—epilepsy syndrome	2.49e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—YWHAZ—epilepsy syndrome	2.48e-06	2.9e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL2—epilepsy syndrome	2.47e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRA2A—epilepsy syndrome	2.46e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NGF—epilepsy syndrome	2.45e-06	2.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLAT—epilepsy syndrome	2.45e-06	2.87e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HES1—epilepsy syndrome	2.39e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR5—epilepsy syndrome	2.38e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BDKRB2—epilepsy syndrome	2.36e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL12—epilepsy syndrome	2.36e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—POMC—epilepsy syndrome	2.36e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HES1—epilepsy syndrome	2.36e-06	2.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PRKCB—epilepsy syndrome	2.35e-06	2.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6ST—epilepsy syndrome	2.34e-06	2.74e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HTR2A—epilepsy syndrome	2.33e-06	2.73e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FYN—epilepsy syndrome	2.32e-06	2.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUNB—epilepsy syndrome	2.32e-06	2.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CNR1—epilepsy syndrome	2.32e-06	2.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—H2AFX—epilepsy syndrome	2.31e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLCB1—epilepsy syndrome	2.31e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MEF2C—epilepsy syndrome	2.31e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FYN—epilepsy syndrome	2.29e-06	2.68e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—H2AFX—epilepsy syndrome	2.28e-06	2.67e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MEF2C—epilepsy syndrome	2.28e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR7—epilepsy syndrome	2.26e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FGF2—epilepsy syndrome	2.23e-06	2.61e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—YWHAZ—epilepsy syndrome	2.23e-06	2.61e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TSC2—epilepsy syndrome	2.22e-06	2.59e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AGT—epilepsy syndrome	2.21e-06	2.59e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NGF—epilepsy syndrome	2.21e-06	2.58e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—YWHAZ—epilepsy syndrome	2.2e-06	2.57e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HBEGF—epilepsy syndrome	2.2e-06	2.57e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NGF—epilepsy syndrome	2.18e-06	2.55e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—epilepsy syndrome	2.17e-06	2.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT3—epilepsy syndrome	2.16e-06	2.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR5—epilepsy syndrome	2.15e-06	2.51e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—POMC—epilepsy syndrome	2.14e-06	2.51e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KDR—epilepsy syndrome	2.13e-06	2.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR5—epilepsy syndrome	2.12e-06	2.48e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADAM10—epilepsy syndrome	2.11e-06	2.46e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR2A—epilepsy syndrome	2.1e-06	2.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL2—epilepsy syndrome	2.1e-06	2.45e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RELA—epilepsy syndrome	2.07e-06	2.42e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR2A—epilepsy syndrome	2.07e-06	2.42e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	2.06e-06	2.41e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PRKCB—epilepsy syndrome	2.05e-06	2.39e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6ST—epilepsy syndrome	2.04e-06	2.38e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MTOR—epilepsy syndrome	2.03e-06	2.38e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	2.01e-06	2.35e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	2e-06	2.34e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TSC2—epilepsy syndrome	2e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGT—epilepsy syndrome	1.99e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—S100B—epilepsy syndrome	1.99e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SOCS3—epilepsy syndrome	1.97e-06	2.31e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TSC2—epilepsy syndrome	1.97e-06	2.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDC42—epilepsy syndrome	1.97e-06	2.3e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGT—epilepsy syndrome	1.97e-06	2.3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—epilepsy syndrome	1.95e-06	2.28e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—epilepsy syndrome	1.93e-06	2.25e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KDR—epilepsy syndrome	1.91e-06	2.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AVP—epilepsy syndrome	1.91e-06	2.23e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—epilepsy syndrome	1.89e-06	2.21e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—epilepsy syndrome	1.89e-06	2.21e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—epilepsy syndrome	1.87e-06	2.19e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—POMC—epilepsy syndrome	1.86e-06	2.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PRKCB—epilepsy syndrome	1.84e-06	2.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6ST—epilepsy syndrome	1.83e-06	2.14e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL2—epilepsy syndrome	1.82e-06	2.13e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PRKCB—epilepsy syndrome	1.82e-06	2.12e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—epilepsy syndrome	1.82e-06	2.12e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6ST—epilepsy syndrome	1.81e-06	2.12e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HES1—epilepsy syndrome	1.8e-06	2.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—epilepsy syndrome	1.77e-06	2.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FYN—epilepsy syndrome	1.75e-06	2.05e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—H2AFX—epilepsy syndrome	1.75e-06	2.04e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MEF2C—epilepsy syndrome	1.74e-06	2.04e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.72e-06	2.01e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—epilepsy syndrome	1.71e-06	2e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.71e-06	2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—YWHAZ—epilepsy syndrome	1.68e-06	1.97e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—POMC—epilepsy syndrome	1.68e-06	1.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NGF—epilepsy syndrome	1.67e-06	1.95e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—POMC—epilepsy syndrome	1.66e-06	1.94e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGF2—epilepsy syndrome	1.65e-06	1.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—epilepsy syndrome	1.64e-06	1.92e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.63e-06	1.91e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—epilepsy syndrome	1.63e-06	1.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR5—epilepsy syndrome	1.62e-06	1.89e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—epilepsy syndrome	1.62e-06	1.89e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.61e-06	1.89e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TH—epilepsy syndrome	1.61e-06	1.88e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—epilepsy syndrome	1.59e-06	1.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR2A—epilepsy syndrome	1.59e-06	1.85e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—epilepsy syndrome	1.54e-06	1.8e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RELA—epilepsy syndrome	1.53e-06	1.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSC2—epilepsy syndrome	1.51e-06	1.76e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGT—epilepsy syndrome	1.5e-06	1.76e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MTOR—epilepsy syndrome	1.5e-06	1.75e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGF2—epilepsy syndrome	1.48e-06	1.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—epilepsy syndrome	1.47e-06	1.72e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGF2—epilepsy syndrome	1.46e-06	1.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—epilepsy syndrome	1.44e-06	1.69e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—epilepsy syndrome	1.39e-06	1.63e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCB—epilepsy syndrome	1.39e-06	1.63e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6ST—epilepsy syndrome	1.38e-06	1.62e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—epilepsy syndrome	1.38e-06	1.61e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RELA—epilepsy syndrome	1.38e-06	1.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RELA—epilepsy syndrome	1.36e-06	1.59e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MTOR—epilepsy syndrome	1.35e-06	1.58e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.34e-06	1.57e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—epilepsy syndrome	1.34e-06	1.57e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MTOR—epilepsy syndrome	1.33e-06	1.56e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.32e-06	1.55e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—epilepsy syndrome	1.3e-06	1.52e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.29e-06	1.51e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—POMC—epilepsy syndrome	1.27e-06	1.48e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—epilepsy syndrome	1.26e-06	1.48e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.25e-06	1.47e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—epilepsy syndrome	1.24e-06	1.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—epilepsy syndrome	1.24e-06	1.45e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—epilepsy syndrome	1.24e-06	1.45e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—epilepsy syndrome	1.23e-06	1.43e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—epilepsy syndrome	1.21e-06	1.41e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—epilepsy syndrome	1.2e-06	1.41e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.2e-06	1.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—epilepsy syndrome	1.19e-06	1.39e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—epilepsy syndrome	1.17e-06	1.37e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—epilepsy syndrome	1.17e-06	1.37e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—epilepsy syndrome	1.16e-06	1.35e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—epilepsy syndrome	1.14e-06	1.33e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—epilepsy syndrome	1.12e-06	1.31e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGF2—epilepsy syndrome	1.12e-06	1.31e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—epilepsy syndrome	1.08e-06	1.27e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—epilepsy syndrome	1.07e-06	1.25e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—epilepsy syndrome	1.05e-06	1.23e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AGT—epilepsy syndrome	1.05e-06	1.23e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—epilepsy syndrome	1.04e-06	1.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RELA—epilepsy syndrome	1.04e-06	1.22e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—epilepsy syndrome	1.03e-06	1.2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MTOR—epilepsy syndrome	1.02e-06	1.19e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—epilepsy syndrome	1.01e-06	1.18e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—epilepsy syndrome	9.46e-07	1.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—epilepsy syndrome	9.38e-07	1.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—epilepsy syndrome	9.11e-07	1.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—epilepsy syndrome	8.86e-07	1.04e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—POMC—epilepsy syndrome	8.84e-07	1.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—epilepsy syndrome	8.59e-07	1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—epilepsy syndrome	8.17e-07	9.55e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—epilepsy syndrome	8.06e-07	9.42e-06	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—epilepsy syndrome	7.96e-07	9.3e-06	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—epilepsy syndrome	7.47e-07	8.73e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	7.05e-07	8.24e-06	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—epilepsy syndrome	6.72e-07	7.86e-06	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—epilepsy syndrome	6.64e-07	7.76e-06	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—epilepsy syndrome	5.08e-07	5.94e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—epilepsy syndrome	3.54e-07	4.14e-06	CbGpPWpGaD
